Mixed HCV infection and reinfection in people who inject drugs-impact on therapy

Nature Reviews Gastroenterology and Hepatology

Volumn 12, Issue 4, 2015, Pages 218-230

  Cunningham, Evan B ^a   Applegate, Tanya L ^a   Lloyd, Andrew R ^b   Dore, Gregory J ^a   Grebely, Jason ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; DACLATASVIR; INTERFERON; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

5' UNTRANSLATED REGION; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; EXPOSURE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK BEHAVIOR; HISTORY; HUMAN; MICROBIAL DIVERSITY; MIXED INFECTION; NAMED GROUPS OF PERSONS; NEXT GENERATION SEQUENCING; NONHUMAN; PEOPLE WHO INJECT DRUGS; PREVALENCE; PRIORITY JOURNAL; REINFECTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SUPERINFECTION; TREATMENT OUTCOME; COINFECTION; HEALTH; RECURRENT DISEASE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE;

ANTIVIRAL AGENTS; COINFECTION; GLOBAL HEALTH; HEPATITIS C; HUMANS; INTERFERONS; PREVALENCE; RECURRENCE; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 84926420358     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2015.36     Document Type: Review

References (150)

1. Nelson P. K., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378, 571-583 (2011
2. Grebely J. & Dore G. J. Can hepatitis C virus infection be eradicated in people who inject drugs?. Antiviral Res. 104, 62-72 (2014
3. Hajarizadeh B., Grebely J. & Dore G. J. Epidemiology and natural history of HCV infection. Nat. Rev. Gastroenterol. Hepatol. 10, 553-562 (2013
4. Grebely J., et al. Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting 1996-2012. PLoS ONE 9, e97726 (2014
5. Hadland S. E., et al. Prescription opioid injection and risk of hepatitis C in relation to traditional drugs of misuse in a prospective cohort of street youth. BMJ Open 4, e005419 (2014
6. Page K., Morris M. D., Hahn J. A., Maher L. & Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin. Infect. Dis. 57 (Suppl. 2), S32-S38 (2013
7. Osburn W. O., et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138, 315-324 (2010
8. Grebely J., et al. Hepatitis C virus clearance reinfection and persistence with insights from studies of injecting drug users: towards a vaccine. Lancet Infect. Dis. 12, 408-414 (2012
9. Elliot L. N., Lloyd A. R., Ziegler J. B. & Ffrench R. A. Protective immunity against hepatitis C virus infection. Immunol. Cell Biol. 84, 239-249 (2006
10. Abdel-Hakeem M. S. & Shoukry N. H. Protective immunity against hepatitis C: many shades of gray. Front. Immunol. 5, 274 (2014
11. Bowden S., McCaw R., White P. A., Crofts N. & Aitken C. K. Detection of multiple hepatitis C virus genotypes in a cohort of injecting drug users. J. Viral Hep. 12, 322-324 (2005
12. Diamantis I., et al. Genotype distribution of hepatitis C virus infection in Greece: correlation with different risk factors and response to interferon therapy. Eur. J. Gastroenterol. Hepatol. 10, 75-79 (1998
13. Herring B. L., Page-Shafer K., Tobler L. H. & Delwart E. L. Frequent hepatitis C virus superinfection in injection drug users. J. Infect. Dis. 190, 1396-1403 (2004
14. Ye Y., et al. Molecular epidemiology of hepatitis C virus among different groups of people in the province of Fujian China. Arch. Virol. 158, 611-618 (2013
15. Lee Y. M., et al. Molecular epidemiology of HCV genotypes among injection drug users in Taiwan: full-length sequences of two new subtype 6w strains and a recombinant form 2b6w. J. Med. Virol. 82, 57-68 (2010
16. Micalessi M. I., et al. Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centers in Belgium 2004-2005. J. Med. Virol. 80, 640-645 (2008
17. Rios-Olivares E., et al. HCV genotype analysis in HCV HIV co-infected Puerto Ricans who are injecting drug users: undetermined and mixed infections. Cell. Mol. Biol. (Noisy le Grand France) 47, 1017-1024 (2001
18. Sereno S., Perinelli P. & Laghi V. Changes in the prevalence of hepatitis C virus genotype among Italian injection drug users-relation to period of injection started. J. Clin. Virol. 45, 354-357 (2009
19. White P. A., Li Z., Zhai X., Marinos G. & Rawlinson W. D. Mixed viral infection identified using heteroduplex mobility analysis (HMA). Virology 271, 382-389 (2000
20. Chen B. F., et al. High prevalence of mixed genotype infections in hepatitis B virus infected intravenous drug users. J. Med. Virol. 74, 536-542 (2004
21. Blackard J. T. HCV superinfection and reinfection. Antivir. Ther. 17, 1443-1448 (2012
22. Blackard J. T. & Sherman K. E. Hepatitis C virus coinfection and superinfection. J. Infect. Dis. 195, 519-524 (2007
23. Grebely J., et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology 55, 1058-1069 (2012
24. Van De Laar T. J., et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J. Hepatol. 51, 667-674 (2009
25. Pham S. T., et al. Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology 52, 1564-1572 (2010
26. Giannini C., et al. Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease. J. Lab. Clin. Med. 134, 68-73 (1999
27. Currie S. L., et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend. 93, 148-54 (2008
28. Mehta S. H., et al. Protection against persistence of hepatitis C. Lancet 359, 1478-1483 (2002
29. Micallef J. M., Kaldor J. M. & Dore G. J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral Hep. 13, 34-41 (2006
30. Grebely J., et al. Hepatitis C virus reinfection in injection drug users. Hepatology 44, 1139-1145 (2006
31. Aitken C. K., et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 48, 1746-1752 (2008
32. Dove L., et al. Viral evolution of hepatitis C in injection drug users. J. Viral Hep. 12, 574-583 (2005
33. Micallef J. M., et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J. Viral Hep. 14, 413-418 (2007
34. Page K., et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection resolution and reinfection. J. Infect. Dis. 200, 1216-1226 (2009
35. Backmund M., Meyer K. & Edlin B. R. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin. Infect. Dis. 39, 1540-1543 (2004
36. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin. Infect. Dis. 40 (Suppl. 5), S336-338 (2005
37. Bate J. P., Colman A. J., Frost P. J., Shaw D. R. & Harley H. A. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C. J. Gastroenterol. Hepatol. 25, 1276-1280 (2010
38. Grady B. P., et al. Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam. Eur. J. Gastroenterol. Hepatol. 24, 1302-1307 (2012
39. Grebely J., et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J. Gastroenterol. Hepatol. 25, 1281-1284 (2010
40. Marco A., et al. Hepatitis C Virus Reinfection among Prisoners with Sustained Virological Response after Treatment for Chronic Hepatitis C. J. Hepatol. 59, 45-51 (2013
41. Hilsden R. J., Macphail G., Grebely J., Conway B. & Lee S. S. Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial. Clin. Infect. Dis. 57 (Suppl. 2), S90-96 (2013
42. McHutchison J. G., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360, 1827-1838 (2009
43. Sherman K. E., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 365, 1014-1024 (2011
44. Kohli A., Shaffer A., Sherman A. & Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 312, 631-640 (2014
45. Loulergue P., Mir O. & Sogni P. Super-infection with genotype 4 hepatitis C virus in a patient treated for genotype 3 acute hepatitis C. AIDS 26, 655-656 (2012
46. Schroter M., Feucht H. H., Zollner B., Schafer P. & Laufs R. Multiple infections with different HCV genotypes: prevalence and clinical impact. J. Clin. Virol. 27, 200-204 (2003
47. Abdelrahman T., et al. Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment. Hepatology 61, 88-97 (2014
48. McNaughton A. L., Thomson E. C., Templeton K., Gunson R. N. & Leitch E. C. Mixed genotype hepatitis C infections and implications for treatment. Hepatology 59, 1209 (2014
49. Bartenschlager R. & Lohmann V. Replication of hepatitis C virus. J. Gen. Virol. 81, 1631-1648 (2000
50. Duffy S., Shackelton L. A. & Holmes E. C. Rates of evolutionary change in viruses: patterns and determinants. Nat. Rev. Genet. 9, 267-276 (2008
51. Jackowiak P., et al. Phylogeny and molecular evolution of the hepatitis C virus. Infect. Genet. Evol. 21, 67-82 (2014
52. Galli A. & Bukh J. Comparative analysis of the molecular mechanisms of recombination in hepatitis C virus. Trends Microbiol. 22, 354-364 (2014
53. Gonzalez-Candelas F., Lopez-Labrador F. X. & Bracho M. A. Recombination in hepatitis C virus. Viruses 3, 2006-2024 (2011
54. Hedskog C., et al. Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. Hepatology 61, 471-480 (2014
55. Kalinina O., Norder H., Mukomolov S. & Magnius L. O. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J. Virol. 76, 4034-4043 (2002
56. Palmer B. A., et al. Analysis of the evolution and structure of a complex intrahost viral population in chronic hepatitis C virus mapped by ultradeep pyrosequencing. J. Virol. 88, 13709-13721 (2014
57. Shi W., et al. Recombination in hepatitis C virus: identification of four novel naturally occurring inter-subtype recombinants. PLoS ONE 7, e41997 (2012
58. Stumpf M. P. & Pybus O. G. Genetic diversity and models of viral evolution for the hepatitis C virus. FEMS Microbiol. Lett. 214, 143-152 (2002
59. Smith D. B., et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59, 318-327 (2014
60. Messina J. P., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61, 77-87 (2014
61. Mondelli M. U. & Silini E. Clinical significance of hepatitis C virus genotypes. J. Hepatol. 31 (Suppl. 1), 65-70 (1999
62. Smith D. B., et al. The origin of hepatitis C virus genotypes. J. Gen. Virol. 78, 321-328 (1997
63. Pybus O. G., et al. The epidemic behavior of the hepatitis C virus. Science 292, 2323-2325 (2001
64. Kalinina O., et al. Shift in predominating subtype of HCV from 1b to 3a in St. Petersburg mediated by increase in injecting drug use. J. Med. Virol. 65, 517-524 (2001
65. van Asten L., et al. Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J. Infect. Dis. 189, 292-302 (2004
66. Jacka B., et al. Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver Canada. Hepatology 60, 1571-1580 (2014
67. Romano C. M., et al. Social networks shape the transmission dynamics of hepatitis C virus. PLoS ONE 5, e11170 (2010
68. Dias P. T., et al. Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco California. BMC Infect. Dis. 11, 208 (2011
69. Pybus O. G., Cochrane A., Holmes E. C. & Simmonds P. The hepatitis C virus epidemic among injecting drug users. Infect. Genet. Evol. 5, 131-139 (2005
70. Roman F., et al. Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006. World J. Gastroenterol. 14, 1237-1243 (2008
71. Salehi Moghadam F., et al. Phylogenetic analysis of hepatitis C virus strains and risk factors associated with infection and viral subtypes among Iranian patients. J. Med. Virol. 86, 1342-1349 (2014
72. Samimi-Rad K., et al. Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time. Arch. Virol. 157, 1959-1965 (2012
73. Morice Y., et al. Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. J. Med. Virol. 78, 1296-1303 (2006
74. Frank C., et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355, 887-891 (2000
75. Van De Laar T., et al. Evidence of a large international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 136, 1609-1617 (2009
76. Smith D. M., Richman D. D. & Little S. J. HIV superinfection. J. Infect. Dis. 192, 438-444 (2005
77. Sarrazin C., et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132, 1767-1777 (2007
78. Wang C., et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob. Agents Chemother. 57, 2054-2065 (2013
79. Forns X., et al. Comparative study of three methods for genotyping hepatitis C virus strains in samples from Spanish patients. J. Clin. Microbiol. 34, 2516-2521 (1996
80. Hu Y. W., et al. Comparison and application of a novel genotyping method semiautomated primer-specific and mispair extension analysis and four other genotyping assays for detection of hepatitis C virus mixed-genotype infections. J. Clin. Microbiol. 38, 2807-2813 (2000
81. Quer J., et al. High-resolution hepatitis C virus (HCV) subtyping using NS5B deep sequencing and phylogeny an alternative to current methods. J. Clin. Microbiol. 53, 219-226 (2014
82. Davidson F., et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region. J. Gen. Virol. 76, 1197-1204 (1995
83. Jacka B., et al. Sequencing of the hepatitis C virus: a systematic review. PLoS ONE 8, e67073 (2013
84. Tsiatis A. C., et al. Comparison of Sanger sequencing pyrosequencing and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J. Mol. Diagn. 12, 425-432 (2010
85. Barzon L., et al. Next-generation sequencing technologies in diagnostic virology. J. Clin. Virol. 58, 346-350 (2013
86. Buermans H. P. & Den Dunnen J. T. Next generation sequencing technology: advances and applications. Biochim. Biophys. Acta 1842, 1932-1941 (2014
87. Donaldson E. F., Harrington P. R., O'Rear J. J. & Naeger L. K. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 61, 56-65 (2015
88. Liu L., et al. Comparison of next-generation sequencing systems. J. Biomed. Biotech. 2012, 251364 (2012
89. Quinones-Mateu M. E., Avila S., Reyes-Teran G. & Martinez M. A. Deep sequencing: becoming a critical tool in clinical virology. J. Clin. Virol. 61, 9-19 (2014
90. Fonseca N. A., Rung J., Brazma A. & Marioni J. C. Tools for mapping high-throughput sequencing data. Bioinformatics 28, 3169-3177 (2012
91. Marz M., et al. Challenges in RNA virus bioinformatics. Bioinformatics 30, 1793-1799 (2014
92. McElroy K., Thomas T. & Luciani F. Deep sequencing of evolving pathogen populations: applications errors and bioinformatic solutions. Microb. Inform. Exp. 4, 1 (2014
93. Nelson C. W. & Hughes A. L. Within-host nucleotide diversity of virus populations: insights from next-generation sequencing. Infect. Genet. Evol. 30, 1-7 (2014
94. Pujol F. H., Devesa M., Loureiro C. L., Capriles F. & Liprandi F. Turnover of hepatitis C virus genotypes in hemodialysis patients. Arch. Virol. 143, 823-827 (1998
95. Laskus T., et al. Exposure of hepatitis C virus (HCV) RNA-positive recipients to HCV RNA-positive blood donors results in rapid predominance of a single donor strain and exclusion and/or suppression of the recipient strain. J. Virol. 75, 2059-2066 (2001
96. Eyster M. E., Sherman K. E., Goedert J. J., Katsoulidou A. & Hatzakis A. Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study. J. Infect. Dis. 179, 1062-1069 (1999
97. Jarvis L. M., et al. Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J. Infect. Dis. 170, 1018-1022 (1994
98. Kao J. H., Chen P. J., Lai M. Y. & Chen D. S. Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis. Gastroenterology 105, 583-587 (1993
99. Lai M. E., et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 343, 388-390 (1994
100. Widell A., et al. Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney. Transplantation 60, 642-647 (1995
101. Kao J. H., et al. Superinfection by homotypic virus in hepatitis C virus carriers: studies on patients with post-transfusion hepatitis. J. Med. Virol. 50, 303-308 (1996
102. Accapezzato D., Fravolini F., Casciaro M. A. & Paroli M. Hepatitis C flare due to superinfection by genotype 4 in an HCV genotype 1b chronic carrier. Eur. J. Gastroenterol. Hepatol. 14, 879-881 (2002
103. Ghosn J., et al. Sexually transmitted hepatitis C virus superinfection in HIV/hepatitis C virus co-infected men who have sex with men. AIDS 22, 658-661 (2008
104. Okamoto H., et al. Superinfection of chimpanzees carrying hepatitis C virus of genotype II/1b with that of genotype III/2a or I/1a. Hepatology 20, 1131-1136 (1994
105. Lau J. Y., et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann. Intern. Med. 124, 868-876 (1996
106. van Asten L. & Prins M. Infection with concurrent multiple hepatitis C virus genotypes is associated with faster HIV disease progression. AIDS 18, 2319-2324 (2004
107. Viazov S., Widell A. & Nordenfelt E. Mixed infection with two types of hepatitis C virus is probably a rare event. Infection 28, 21-25 (2000
108. Stamenkovic G., et al. Distribution of HCV genotypes among risk groups in Serbia. Eur. J. Epidemiol. 16, 949-954 (2000
109. Aitken C., et al. Change in hepatitis C virus genotype in injecting drug users. J. Med. Virol. 74, 543-545 (2004
110. Antipa C., Ruta S. & Cernescu C. Serological profile assessment of the infection with hepatitis C virus (HCV) in haemophiliacs and thalassemic patients. Rom. J. Virol. 47, 3-11 (1996
111. Natov S. N., et al. Serologic and virologic profiles of hepatitis C infection in renal transplant candidates. New England Organ Bank Hepatitis C Study Group. Am. J. Kidney Dis. 31, 920-927 (1998
112. Wu J. S., et al. Genotype distribution of hepatitis C virus infection in Taiwan. J. Med. Virol. 44, 74-79 (1994
113. Qian K. P., Natov S. N., Pereira B. J. & Lau J. Y. Hepatitis C virus mixed genotype infection in patients on haemodialysis. J. Viral Hep. 7, 153-160 (2000
114. Boelen L., et al. Per-event probability of hepatitis C infection during sharing of injecting equipment. PLoS ONE 9, e100749 (2014
115. Grebely J., et al. The effects of female sex viral genotype and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 59, 109-120 (2014
116. Osburn W. O., et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138, 315-324 (2009
117. McHutchison J. G., et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339, 1485-1492 (1998
118. Manns M. P., et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965 (2001
119. Jacobson I. M., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405-2416 (2011
120. Poordad F., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1195-1206 (2011
121. Razavi H., Estes C., Pasini K., Gower E. & Hindman S. HCV treatment rate in select European countries in 2004-2010. J. Hepatol. 58, S22-S23 (2013
122. Liang T. J. & Ghany M. G. Therapy of hepatitis C-back to the future. N. Engl. J. Med. 370, 2043-2047 (2014
123. Ferenci P., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N. Engl. J. Med. 370, 1983-1992 (2014
124. Feld J. J., et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370, 1594-1603 (2014
125. Poordad F., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N. Engl. J. Med. 370, 1973-1982 (2014
126. Everson G. T., et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir asunaprevir and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 146, 420-429 (2014
127. Afdhal N., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370, 1889-1898 (2014
128. Afdhal N., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 370, 1483-1493 (2014
129. Lawitz E., et al. Efficacy and safety of MK-5172 and MK-8742 ± ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null response: the C-WORTHY Study. [abstract 196]. Hepatology 60 (Suppl. 1), S25-S26 (2014
130. Gane E. J., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34-44 (2013
131. Zeuzem S., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N. Engl. J. Med. 370, 1993-2001 (2014
132. McPhee F., et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob. Agents Chemother. 56, 5387-5396 (2012
133. Lawitz E., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368, 1878-1887(2013
134. Link J. O., et al. Discovery of ledipasvir (GS-5885): a potent once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J. Med. Chem. 57, 2033-2046 (2014
135. Lawitz E., et al. Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. J. Infect. 70, 197-205 (2014
136. Summa V., et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob. Agents Chemother. 56, 4161-4167 (2012
137. Everson G. T., et al. Safety and efficacy of treatment with interferon-free ribavirin-free combination of sofosbuvir + GS-5816 for 12 weeks in treatment naïve patients with genotype 1-6 HCV infection [abstract 0111]. J. Hepatol. 60, S46 (2014
138. Tran T. T., et al. Safety and efficacy of treatment with sofosbuvir + GS-5816 ± ribavirin for 8 or 12 weeks in treatment naive patients with genotype 1-6 HCV infection. [abstract 80]. Hepatology 60 (Suppl. 1), 237A (2014
139. Nelson D. R., Cooper J. N., Lalezari J. P. & Lawitz E. All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in patients infected with HCV genotype (GT) 3: ALLY-3 phase 3 study. [abstract LB3]. Hepatology 60 (Suppl. 1) (2014
140. Izquierdo L., et al. Simeprevir for the treatment of hepatitis C virus infection. Pharmacogenomics Pers. Med. 7, 241-249 (2014
141. Kao J. H., Lai M. Y., Chen P. J. & Chen D. S. Probable reinfection with hepatitis C virus in a chronic hepatitis C patient with a sustained response to combination therapy. J. Formos. Med. Assoc. 100, 824-828 (2001
142. Akuta N., et al. Interferon-alpha for reinfection with hepatitis C virus in two patients with chronic hepatitis C who had responded to previous therapies. Dig. Dis. Sci. 48, 1654-1657 (2003
143. Asselah T., et al. Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy. Gut 52, 900-902 (2003
144. Backmund M., Meyer K., Von Zielonka M. & Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 34, 188-193 (2001
145. Aspinall E. J., et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin. Infect. Dis. 57 (Suppl 2), S80-S89 (2013
146. Hill A. M., Saleem J., Heath K. A. & Simmons B. Effects of sustained virological response (SVR) on the risk of liver transplant hepatocellular carcinoma death and re-infection: meta-analysis of 129 studies in 23,309 patients with hepatitis C infection. [abstract 44]. Hepatology 60 (Suppl. 1), 218A (2014
147. Bretaña N. A., et al. Hepatitis C virus transmission dynamics in a high-risk incarcerated population. Emerg. Infect. Dis. (in press
148. Parodi C., et al. Evidence of occult HCV genotypes in haemophilic individuals with unapparent HCV mixed infections. Haemophilia 14, 816-822 (2008
149. Thomson E. C., et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV 1 infected men. Gut 60, 837-845 (2011
150. Wu S., et al. Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region. PLoS ONE 8, e73615 (2013